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Background: Medical grade manuka honeys are well known to be efficacious against Pseudomonas aeruginosa
being bactericidal and inhibiting the development of biofilms; moreover manuka honey effectively kills P. aeruginosa
embedded within an established biofilm. Sustained honey resistance has not been previously documented for
planktonic or biofilm P. aeruginosa.
Methods: Minimum inhibitory concentrations for manuka honey and antibiotics were determined using broth
micro-dilution methods. Minimum biofilm eliminating concentrations (MBEC) and biofilm biomass were determined using
the crystal violet method. Sub-culture used non-selective media and the grid-plate method.
Results: When honey treated biofilm biomass of two strains of P. aeruginosa (reference strain ATCC 9027 and the clinical
isolate 867) were sub-cultured onto non-selective media isolates emerged that exhibited reduced susceptibility to manuka
honey. Significantly, this characteristic was sustained with repeated sub-culture onto non-selective media resulting in
increased minimum inhibitory concentrations (MIC) of between 5-7% (w/v) and increased minimum biofilm eliminating
concentrations (MBEC) of up to 15% (w/v). Interestingly the resistant isolates showed reduced susceptibility to antibiotic
treatment with rifampicin and imipenem as well as being more prolific biofilm-formers than the progenitor strains.
Conclusions: P. aeruginosa biofilms treated with manuka honey equivalent to the MBEC harbour slow growing, viable
persistor organisms that exhibit sustained, increased resistance to manuka honey and antibiotic treatment, suggesting a
shared mechanism of resistance. This sheds new light on the propensity for biofilm embedded organisms to resist honey
treatment and become persistor organisms that are tolerant to other antimicrobial therapies.
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Honey has been long utilised as a topical antimicrobial
treatment for wound infection, with licensed medical
products becoming available in the 1990’s. Whilst often
still used as a last line treatment when other therapies
have failed, manuka honey is broad spectrum with potent
bactericidal activity. Some of the bacterial cellular targets
for manuka honey are now known and more continue to
be identified. For Gram positive organisms the primary
mode of action is to disrupt the cell cycle leading to aber-
rant cell division and weakening of the cell wall; this is
combined with an up-regulation of the general stress
response [1,2]. In Gram negative organisms, particularly* Correspondence: smaddocks@cardiffmet.ac.uk
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article, unless otherwise stated.Pseudomonas aeruginosa, the major targets appear to be
integral membrane proteins such as OprF which ordinar-
ily stabilise the cell leaflet and without which, extensive
membrane disruption and eventual lysis occurs [3].
Essentially, studies have demonstrated that with short-
and long-term training experiments, no resistance to
manuka honey treatment emerges [4,5]. This is of particu-
lar significance in an age where antimicrobial resistance
outstrips the rate at which new antimicrobial treatments
are discovered and where there is real concern that species
resistant to all known antibiotics could become rife. The
problem of resistance can be exacerbated, for example
when microorganisms grow as a biofilm. Such organisms
are afforded intrinsic protection in the form of an
extra-polysaccharide layer which restricts the diffusioned Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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reach all bacteria within the biofilm, causing infection
to recur [6,7]. Therefore the biofilm mode of growth, by
hindering diffusion, could provide an ideal environment
whereby microorganisms are exposed to sub-lethal doses
of antimicrobial thus providing a selective pressure for the
emergence of resistance.
Previous studies have shown that following treatment of
established biofilms of P. aeruginosa biofilms, the bacterial
biomass appears non-viable by fluorescent microscopy,
but with a large amount remaining attached to the sub-
stratum [8]. This study aimed to determine whether viable
cells were in fact present within this biomass, since the
published data showed only top-views of biofilms [8]
rather than three-dimensional Z-stacks that might have
revealed any embedded viable bacteria, deeper within
the biofilm, and if so to ascertain whether these persistors
exhibited resistance to manuka honey treatment. Here
we report that isolates of P. aeruginosa, recovered from
manuka honey treated biofilms, which appeared to contain
only non-viable biomass, exhibited increased resistance
to manuka honey treatment, a trait that was sustained
despite repeated sub-culture. These isolates were also
more resistant to other antibiotics and demonstrated
enhanced biofilm forming capacity.Methods
Bacterial strains
P. aeruginosa reference strain ATCC 9027 (NCIMB 8626)
and the clinical isolate 867 were used throughout the study.
The clinical isolate was from a wound swab collected from
a patient with a chronic wound who attended an out-
patient clinic at the University Hospital of Wales, Cardiff.
All strains were cultured aerobically at 37°C in nutrient
broth (NB). Biofilms were cultured in 5 ml NB supple-
mented with manuka honey at the appropriate MBEC
(50% w/v for ATCC 9207 and 45% w/v for 867) in a sterile
plastic Petri dish for 48 h at 37°C, biomass was recovered
by scraping the plate into 1 ml PBS, re-suspending by vor-
tex and lawn plating onto nutrient agar (NA), these were
incubated at 37°C for 48 h. Isolates were confirmed as P.
aeruginosa by Gram stain, oxidase test and production of
blue/green pigment. Isolates were sub-cultured every 48 h
for two weeks onto non-selective media to confirm that
any observed resistance was a sustained and not transient.Manuka honey
Sterile (gamma irradiated) medical grade manuka honey
(Medihoney™) was purchased from Comvita in 50 g
tubes, and is available as a licensed, commercial medical
device (Comvita, Berkshire, UK). It is supplied as a standar-
dised, 100% pure honey derived from the Leptospermum
scoparium plant in New Zealand.Minimum inhibitory concentration
Minimum inhibitory concentrations (MIC) for manuka
honey were determined using a range of concentrations
of 0-50% (w/v), in increments of 2%), in a total volume
of 50 μl nutrient broth in a 96 well microtitre plate
(Oxoid, Cambridge, UK). Plates were incubated for 48 h
to allow for slow growth of the recovered isolates, at 37°C
in aerobic conditions. Assays were carried out in triplicate
on each of three separate occasions. MIC readings were
taken using a Spectrostar Nano spectrophotometer (BMG
Labtech) at A650. MICs for imipenem and rifampicin were
determined by preparing doubling dilutions ranging from
0-64 μg ml−1 in a total volume of 50 μl NB. These antibi-
otics were chosen due to their known efficacy against the
two strains of P. aeruginosa used in this study [9,10].
Plates were incubated and read as described above.
Minimum biofilm eliminating concentration
Microorganisms were cultured to mid-exponential phase,
harvested by centrifugation, and adjusted to OD650 = 0.1.
Biofilms were established in 96 well microtitre plates
(Greiner) in 50 μl NB containing a range of concentra-
tions of manuka honey from 0-80% (w/v; increments of
5%), by inoculating each well with 5 μl of equilibrated
cells. Plates were incubated at 37°C for 48 h. To determine
biofilm growth, unattached cells were gently aspirated and
discarded, adherent cells were washed twice with PBS and
then stained with crystal violet (0.25% w/v) for 10 min.
After a subsequent two washes with PBS, cell-bound
crystal violet was re-solubilized with 7% acetic acid, and
absorbance measured at A595 [11].
Biofilm biomass assay
Microorganisms were cultured to mid-exponential phase,
harvested by centrifugation, and adjusted to OD650 = 0.1.
Biofilms of recovered isolates were established in 96 well
microtitre plates (Greiner) in 50 μl NB, by inoculating
each well with 5 μl of equilibrated cells. Plates were
incubated at 37°C for 48 h. Biomass was determined as
described above.
Statistical analysis
Triplicate sets of biological replicates were used for each
experiment and each assay was repeated three times;
statistical analysis utilized Minitab (version 14; Students
T-test). Statistically significance data are defined as having
P values that were equal to, or less than 0.05.
Results
Isolates recovered from biofilm biomass showed
sustained, increased resistance to manuka honey
treatment when cultured planktonically and as a biofilm
The MIC for the reference strain ATCC 9027 was lower
than the recovered isolate, being 25.6% (w/v) and 30.6%
Table 1 Sensitivity of progenitor strains P. aeruginosa
ATCC 9027 and clinical isolate 867 and their recovered
isolates (from honey treated biofilm) to manuka honey
treatment using the microbroth dilution method
Mean MIC% (w/v) ± SE
P. aeruginosa ATCC 9027 P. aeruginosa 867
Progenitor strain 25.6 ± 0.6 15.3 ± 0.6
Recovered isolate 30.6 ± 0.6 22.6 ± 0.6
p-value <0.05 <0.05
SE = standard error of the mean.
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isolate, strain 867 showed an increase in MIC from 15.3%
(w/v) for the progenitor to 22.6% (w/v) for the recovered
isolate (p < 0.05). Likewise, each recovered isolate had
higher MBEC values than the progenitor strain, for ATCC
9027 MBEC increased from 48.3% (w/v) to 63.3% (w/v)
(p < 0.05) and for the clinical isolate 867 the MBEC in-
creased from 43.3% (w/v) to 50% (w/v) (p < 0.05). Following
repeated sub-culture the MIC/MBECs remained consistent
and did not revert to those of the progenitor strains, sug-
gesting that the recovered isolates had developed increased
resistance to manuka honey treatment.
Honey resistant isolates demonstrated increased
resistance to treatment with rifampicin and imipenem
To determine whether the observed increase in tolerance
to manuka honey treatment also conferred increased
resistance to antibiotics, MICs for each of the progenitor
and recovered isolates using rifampicin and imipenem were
established. Both recovered isolates exhibited increased
resistance to imipenem and rifampicin (Table 2) with
MICs at least doubling in each case. For ATCC 9027
the MIC for imipenem increased from 2.6 μg ml−1 for
the progenitor to 13.3 μg ml−1 for the recovered isolate
(p < 0.05); with rifampicin the MIC increased from
13.3 μg ml−1 to 32 μg ml−1 (p < 0.05) (Table 2). For
strain 867 the MIC for imipenem increased from
8 μg ml−1 for the progenitor to 21.3 μg ml−1 (p < 0.05)
for the recovered isolate; for rifampicin the MIC
increased from 13.3 μg ml−1 for the progenitor to
32 μg ml−1 (p < 0.05) for the recovered isolate (Table 2).Table 2 Sensitivity of progenitor strains P. aeruginosa ATCC 9
(from honey treated biofilm) to rifampicin and imipenem trea
P. aeruginosa ATCC 9027
Rifampicin Imi
Progenitor strain 13.3 ± 2.6 2.
Recovered isolate 32 ± 0 13
p-value <0.05 <
SE = standard error of the mean.Honey resistant isolates exhibited increased biofilm
forming capacity
When static biofilms of each recovered isolate were
cultured for 48 h and stained with crystal violet, the
biomass appeared markedly increased compared to that of
the progenitor strains cultured under the same conditions
(Table 3). For strain ATCC 9207 a 3.8 fold increase in
biomass was observed for the recovered isolate compared
to the progenitor strain, and for the clinical isolate 867
an increase of 2.1 fold was evident. This suggests that
the recovered isolates have a better capacity for forming
biofilm, despite being slower growing than the progenitor
strains.
Discussion
Excessive and inappropriate use of antimicrobial agents
has long been acknowledged as a driver for the emergence
of resistant strains of bacteria, and there is a correlation
between the availability of an antimicrobial and occur-
rence of resistance within a microbial population [12-15].
This is not limited to antibiotics, resistance to topical
antiseptics and biocides that are often used to treat
wound infection, including chlorhexidine and silver, have
been comprehensively documented [16-19]. Bacteria accli-
matise quickly to antimicrobials; it can be a matter of
months between the introduction of a new antimicrobial
and the appearance of resistant strains. However, when
the selective pressure is removed, by restricted use, a
reduction in the occurrence of resistant isolates is often
observed [5]. Short and long term, step-wise resistance
training has previously demonstrated that neither P.
aeruginosa nor S. aureus develop resistance to honey and
that any increased tolerance to treatment is transient [4,5].
In these studies planktonic cultures were repeatedly sub-
cultured in the presence of sub-inhibitory doses of honey
with MIC values obtained daily with each transfer.
Our study showed that viable, slow growing isolates that
were recovered from the biomass of biofilms treated with
honey and which appeared to be non-viable by fluores-
cent microscopy [8], had increased resistance to manuka
honey treatment. Moreover this was statistically signifi-
cant (p < 0.05) with increased MICs for isolates grown
planktonically and also increased MBECs (Tables 1 and 4).027 and clinical isolate 867 and their recovered isolates
tment using the microbroth dilution method
Mean MIC μg ml−1 ± SE
P. aeruginosa 867
penem Rifampicin Imipenem
6 ± 0.6 8 ± 0 13.3 ± 2.6
.3 ± 2.6 21.3 ± 5.3 32 ± 0
0.05 <0.05 <0.05
Table 3 Increase in biofilm biomass of progenitor strains
P. aeruginosa ATCC 9027 and clinical isolate 867 and
their recovered isolates (from honey treated biofilm)
using the crystal violet method
Biofilm biomass (A595) ± SE
P. aeruginosa ATCC 9027 P. aeruginosa 867
Progenitor strain 0.15 ± 0.01 0.18 ± 0.02
Recovered isolate 0.58 ± 0.1 0.39 ± 0.02
p-value <0.05 <0.05
Fold-increase 3.86 2.16
SE = standard error of the mean.
Camplin and Maddocks Annals of Clinical Microbiology and Antimicrobials 2014, 13:19 Page 4 of 5
http://www.ann-clinmicrob.com/content/13/1/19Repeated sub-culture of the recovered isolates did not
result in reversion to the more susceptible, progenitor
phenotype for either strain (ATCC 9027 and clinical isolate
867). Within the biofilm diffusion of antimicrobial agents
can be impaired by the polysaccharide matrix, resulting in a
failure to reach inhibitory or bactericidal concentrations
throughout the whole biofilm [6,7]. Therefore it is likely
that these sub-inhibitory/sub-lethal levels instead provide a
selective pressure that favours sustained resistance.
It was not possible to investigate possible mechanisms
of resistance within the remit of this study but it was
interesting to note that the honey resistant recovered
isolates of each strain also exhibited increased resistance
to rifampicin and imipenem (Table 2). It is possible there-
fore that mutations have occurred in these strains that
confer cross-resistance to these antimicrobials, but given
the different modes of action of these antimicrobials it
could be hypothesised that the recovered isolates, which
were slower growing than the progenitor strains, were
small colony variants (SCV) of the original isolates. SCVs
can emerge in populations of bacteria that are exposed to
stresses which results in transient or permanent pheno-
typic changes, typically including increased resistance to
antimicrobial treatment [19]. They can occur at a rate of
1.8×10−8 per cell per generation, comprising a small but
persistent proportion of the bacterial population [20]. The
propensity for SCVs to resist antimicrobial treatment is
attributed to their slow growth and impaired electron
transport chain; therefore it is not uncommon for SCVsTable 4 Sensitivity of biofilms of progenitor strains P.
aeruginosa ATCC 9027 and clinical isolate 867 and their
recovered isolates (from honey treated biofilm) to
manuka honey treatment using the crystal violet method
Mean MBEC% (w/v) ± SE
P. aeruginosa ATCC 9027 P. aeruginosa 867
Progenitor strain 48.3 ± 1.6 43.3 ± 1.6
Recovered isolate 63.3 ± 1.6 50 ± 0
p-value <0.05 <0.05
SE = standard error of the mean.to show increased resistance to several different classes
of antimicrobial [21], which might be the case in this
study. Furthermore SCVs characteristically show enhanced
biofilm formation [22] which was observed here and
might also explain why the MBEC for manuka honey was
increased compared to biofilm of the progenitor strains.
The European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST) defines antimicrobial resistant
microorganisms as being resistant by a level of anti-
microbial activity that is likely to result in therapeutic
failure [23]. Licensed medical products containing manuka
honey do so at levels of between 80-95% (w/v) [5] which
exceeds the in vitro MICs and MBECs observed in this
study. However wounds often produce exudate and the
high osmolarity of honey promotes this meaning that
honey is invariably diluted in situ. Since this is highly
dependent on the nature of the wound the actual magni-
tude of dilution is not known and could have the potential
to exacerbate the likelihood of resistance, especially in
infections where biofilm is present. Despite this study
indicating that increased resistance to manuka honey
was concurrent with increased resistance to imipenem
and rifampicin, combined use of these antimicrobials with
honey could outweigh problems that might be associated
with resistance as they have been shown to act synergistic-
ally to increase microbial susceptibility in vitro [9,10];
however such studies did not use biofilms. The authors
are currently investigating the combined effects of honey
and antibiotics on our resistant isolates to ascertain
whether they are susceptible to combination therapy.Conclusions
In conclusion, our studies reveal for the first time that
isolates exposed to manuka honey within an established
biofilm can develop sustained, increased resistance, which
is possibly due to the appearance of small colony variants
within the microbial population. This is a factor that needs
to be taken into consideration in clinical practice where
both biofilm organisms and small colony variants are
often overlooked due to difficulties isolating them by
standard techniques in vitro. Therefore where recalci-
trant or chronic, infected wounds are present it remains
vital to ensure that topical treatments such as manuka
honey are appropriately applied for a suitable length of
time in combination with other antimicrobials where
necessary to ensure that infection is resolved and the
likelihood for resistance is minimised.
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